Farallon Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.3M | Buy |
2,871,862
+99,600
| +4% | +$1.34M | 0.21% | 49 |
|
|
2025
Q4 | $43.7M | Buy |
2,772,262
+650,000
| +31% | +$8.26M | 0.2% | 55 |
|
|
2025
Q3 | $25.4M | Hold |
2,122,262
| – | – | 0.1% | 71 |
|
|
2025
Q2 | $16M | Hold |
2,122,262
| – | – | 0.07% | 75 |
|
|
2025
Q1 | $11.7M | Buy |
2,122,262
+14,000
| +0.7% | +$86.5K | 0.06% | 71 |
|
|
2024
Q4 | $12.1M | Hold |
2,108,262
| – | – | 0.05% | 80 |
|
|
2024
Q3 | $21.8M | Buy |
2,108,262
+13,262
| +0.6% | +$173K | 0.1% | 74 |
|
|
2024
Q2 | $27.2M | Hold |
2,095,000
| – | – | 0.12% | 67 |
|
|
2024
Q1 | $36.6M | Buy |
2,095,000
+70,000
| +3% | +$926K | 0.16% | 61 |
|
|
2023
Q4 | $19.1M | Buy |
2,025,000
+150,000
| +8% | +$1.4M | 0.09% | 70 |
|
|
2023
Q3 | $20.9M | Hold |
1,875,000
| – | – | 0.1% | 72 |
|
|
2023
Q2 | $40.1M | Buy |
1,875,000
+325,000
| +21% | +$9.58M | 0.2% | 71 |
|
|
2023
Q1 | $62.7M | Hold |
1,550,000
| – | – | 0.34% | 56 |
|
|
2022
Q4 | $72.1M | Hold |
1,550,000
| – | – | 0.43% | 55 |
|
|
2022
Q3 | $80.4M | Hold |
1,550,000
| – | – | 0.44% | 60 |
|
|
2022
Q2 | $73.3M | Hold |
1,550,000
| – | – | 0.4% | 63 |
|
|
2022
Q1 | $110M | Sell |
1,550,000
-23,829
| -2% | -$1.55M | 0.53% | 47 |
|
|
2021
Q4 | $118M | Sell |
1,573,829
-421,171
| -21% | -$33.1M | 0.59% | 42 |
|
|
2021
Q3 | $113M | Hold |
1,995,000
| – | – | 0.53% | 50 |
|
|
2021
Q2 | $87.8M | Hold |
1,995,000
| – | – | 0.36% | 57 |
|
|
2021
Q1 | $98.4M | Buy |
1,995,000
+220,000
| +12% | +$11M | 0.49% | 48 |
|
|
2020
Q4 | $74.7M | Hold |
1,775,000
| – | – | 0.45% | 51 |
|
|
2020
Q3 | $81.3M | Buy |
1,775,000
+25,000
| +1% | +$1.21M | 0.56% | 49 |
|
|
2020
Q2 | $87.9M | Hold |
1,750,000
| – | – | 0.7% | 41 |
|
|
2020
Q1 | $90M | Hold |
1,750,000
| – | – | 0.77% | 33 |
|
|
2019
Q4 | $108M | Buy |
1,750,000
+475,788
| +37% | +$29.5M | 0.73% | 35 |
|
|
2019
Q3 | $76.6M | Buy |
1,274,212
+314,212
| +33% | +$23.3M | 0.58% | 41 |
|
|
2019
Q2 | $81M | Buy |
960,000
+20,000
| +2% | +$1.8M | 0.53% | 42 |
|
|
2019
Q1 | $89.8M | Buy |
940,000
+15,000
| +2% | +$1.35M | 0.68% | 41 |
|
|
2018
Q4 | $65.5M | Buy |
925,000
+57,500
| +7% | +$4.41M | 0.48% | 42 |
|
|
2018
Q3 | $74.1M | Sell |
867,500
-207,500
| -19% | -$20.8M | 0.44% | 42 |
|
|
2018
Q2 | $125M | Buy |
1,075,000
+160,000
| +17% | +$16M | 0.77% | 31 |
|
|
2018
Q1 | $74M | Sell |
915,000
-10,000
| -1% | -$770K | 0.51% | 40 |
|
|
2017
Q4 | $54.3M | Buy |
925,000
+512,667
| +124% | +$25.7M | 0.44% | 41 |
|
|
2017
Q3 | $19.3M | Buy |
+412,333
| New | +$16.6M | 0.17% | 59 |
|
Other funds holding ENTA
KAM
DTC
VCM
VPM
SSC
Farallon Capital Management's ENTA Position: Q1 2026 in Review
Farallon Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 3.6% in Q1 2026, buying an estimated $1.34M and bringing the position to 2,871,862 shares worth $36.3M. The position accounts for 0.21% of the portfolio, ranked #49.
Farallon Capital Management first reported a position in ENTA in Q3 2017 and has held it in 35 quarters since. The position peaked at $125M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Farallon Capital Management held 2,871,862 shares of Enanta Pharmaceuticals worth $36.3M as of Q1 2026.
- Farallon Capital Management bought 99,600 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.34M.
- Enanta Pharmaceuticals made up 0.21% of Farallon Capital Management's portfolio in Q1 2026, its #49 holding.
- Farallon Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2017 and has held it in 35 quarters since.
- Farallon Capital Management's Enanta Pharmaceuticals position peaked at $125M in Q2 2018.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.